Aiming at identifying a Myc-targeting therapy that could specifically affect cells with deregulated Myc in vivo, Mo et al. (2006) [121] performed a cellular screen of 1990 NCI compounds to identify those, which preferentially inhibit the proliferation of tumor cells with high Myc expression, but do not affect systems with low Myc levels. The gene discussed is MYC; the disease is neoplasm.